Where do thiazolidinediones, or TZD's, fit in our clinical approach to treating patients with type 2 diabetes? TZD's used early in the course of the disease seem to be a powerful therapy with a substantial reduction in the progression of type 2 diabetes. What does this tell us about the pathogenesis of diabetes? Join host Dr. Steven Edelman and his guest, professor of medicine and chief of the division of endocrinology, diabetes and metabolism of the University of Vermont, Dr. Jack Leahy, as they discuss the pathogenesis of diabetes and the role of thiazolidinediones in the prevention and treatment of type 2 diabetes.
